<DOC>
	<DOCNO>NCT02382796</DOCNO>
	<brief_summary>The purpose study permit continued access dacomitinib patient participate dacomitinib monotherapy treatment protocols Japan potential derive clinical benefit without unacceptable toxicity continue dacomitinib treatment .</brief_summary>
	<brief_title>A Rollover Protocol Dacomitinib For Patients In Japan</brief_title>
	<detailed_description>The intention study allow continue use dacomitinib Japan patient close dacomitinib clinical trial continue experience clinical benefit .</detailed_description>
	<criteria>Patients receive dacomitinib another clinical trial Japan Evidence personally sign date informed consent document Patients meet one study withdrawal criterion prior study Participation study involve investigational drug ( ) study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>